ProMIS Neurosciences (NASDAQ:PMN – Get Rating) and Cingulate (NASDAQ:CING – Get Rating) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, profitability, earnings, analyst recommendations, institutional ownership and dividends.
Analyst Ratings
This is a breakdown of current recommendations for ProMIS Neurosciences and Cingulate, as provided by MarketBeat.
Get
ProMIS Neurosciences alerts:
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
| ProMIS Neurosciences | 0 | 0 | 0 | 0 | N/A |
| Cingulate | 0 | 0 | 3 | 0 | 3.00 |
Volatility & Risk
ProMIS Neurosciences has a beta of 0.75, indicating that its share price is 25% less volatile than the S&P 500. Comparatively, Cingulate has a beta of 0.31, indicating that its share price is 69% less volatile than the S&P 500.
Valuation and Earnings
This table compares ProMIS Neurosciences and Cingulate's gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
| ProMIS Neurosciences | $8,138.00 | 5,227.94 | -$9.40 million | ($1.83) | -2.71 |
| Cingulate | N/A | N/A | -$20.71 million | ($1.48) | -0.67 |
ProMIS Neurosciences has higher revenue and earnings than Cingulate. ProMIS Neurosciences is trading at a lower price-to-earnings ratio than Cingulate, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
12.8% of ProMIS Neurosciences shares are held by institutional investors. Comparatively, 2.4% of Cingulate shares are held by institutional investors. 31.3% of Cingulate shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Profitability
This table compares ProMIS Neurosciences and Cingulate's net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
| ProMIS Neurosciences | N/A | -314.88% | -112.74% |
| Cingulate | N/A | -109.55% | -89.22% |
Summary
Cingulate beats ProMIS Neurosciences on 6 of the 10 factors compared between the two stocks.
About ProMIS Neurosciences
(Get Rating)
ProMIS Neurosciences, Inc. engages in the discovery and development of precision medicine solutions for early detection and effective treatment of neurodegenerative diseases. It focuses on the progression of Alzheimer's disease, amyotrophic lateral sclerosis, and Parkinson's disease. The company was founded by Neil Cashman and Vigen Nazarian on January 23, 2004 and is headquartered in Toronto, Canada.
About Cingulate
(Get Rating)
Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.
Receive News & Ratings for ProMIS Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProMIS Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.
